Moreover, the IMspire150 study demonstrated that the addition of PD-1 monoclonal antibody to targeted therapy was well tolerated and significantly improved PFS in advanced melanoma patients with BRAF V600E mutation [13]. This evidence concerns the gene BRAF and melanoma.